Follow
Christopher Chidley
Christopher Chidley
Harvard Medical School
Verified email at hms.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Directed evolution of O6-alkylguanine-DNA alkyltransferase for applications in protein labeling
T Gronemeyer, C Chidley, A Juillerat, C Heinis, K Johnsson
Protein Engineering, Design and Selection 19 (7), 309-316, 2006
1822006
A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis
C Chidley, H Haruki, MG Pedersen, E Muller, K Johnsson
Nature Chemical Biology 7 (6), 375-383, 2011
1382011
An enhanced isothermal amplification assay for viral detection
J Qian, SA Boswell, C Chidley, Z Lu, ME Pettit, BL Gaudio, JM Fajnzylber, ...
Nature communications 11 (1), 1-10, 2020
832020
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
AC Palmer, C Chidley, PK Sorger
Elife 8, e50036, 2019
542019
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells
L Gerosa, C Chidley, F Fröhlich, G Sanchez, SK Lim, J Muhlich, JY Chen, ...
Cell Systems, 2020
482020
The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine
C Chidley, SA Trauger, K Birsoy, EK O'Shea
Elife 5, e14601, 2016
412016
A designed protein for the specific and covalent heteroconjugation of biomolecules
C Chidley, K Mosiewicz, K Johnsson
Bioconjugate chemistry 19 (9), 1753-1756, 2008
232008
Searching for the protein targets of bioactive molecules
C Chidley, H Haruki, MG Pedersen, C Fellay, S Moser, K Johnsson
CHIMIA International Journal for Chemistry 65 (9), 720-724, 2011
122011
Mutants of O6-alkylguanine-DNA alkyltransferase
J Barnikow, C Chidley, T Gronemeyer, C Heinis, H Jaccard, K Johnsson, ...
US Patent 7,888,090, 2011
82011
Sporadic ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells
L Gerosa, C Chidley, F Froehlich, G Sanchez, SK Lim, J Muhlich, JY Chen, ...
bioRxiv, 762294, 2019
72019
Drugs in a curative combination therapy for lymphoma exhibit low cross-resistance but not pharmacological synergy
AC Palmer, C Chidley, P Sorger
Available at SSRN 3249463, 2018
32018
Abstract LB-B09: ERK pulses drive non-genetic resistance in drug-adapted BRAFV600E melanoma cells
L Gerosa, C Chidley, F Froehlich, G Sanchez, SK Lim, J Muhlich, JY Chen, ...
Molecular Cancer Therapeutics 18 (12_Supplement), LB-B09-LB-B09, 2019
12019
A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy
AC Palmer, C Chidley, PK Sorger
bioRxiv, 462184, 2019
12019
Method of Crosslinking Two Objects of Interest
K Johnsson, C Chidley, K Mosiewicz
US Patent App. 12/594,256, 2010
12010
A Novel Yeast-Based Platform for Small Molecule Target Deconvolution Reveals Previously Unknown Binding Partners for the Approved Drugs Erlotinib, Atorvastatin, and Sulfasalazine
C Chidley
EPFL, 2010
12010
Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress
PP Hsu, BT Do, SY Vermeulen, Z Wang, T Hirz, N Aziz, JM Replogle, ...
bioRxiv, 2022
2022
An enhanced isothermal amplification assay for viral detection (preprint)
J Qian, SA Boswell, C Chidley, ZX Lu, ME Pettit, BL Gaudio, ...
2020
Compositions and use of sulfasalazine
K Johnsson, C Chidley
2011
Directed molecular evolution of protein function
C Chidley
EPFL, 2005
2005
LPPT
V Baeriswyl, S Bellotto, M Bergeron-Brlek, D Bertoldo, MP Biedermann, ...
The system can't perform the operation now. Try again later.
Articles 1–20